Management of empyema cavity with the vacuum-assisted closure device.

K. A. Varker,T. Ng

DOI: https://doi.org/10.1016/J.ATHORACSUR.2004.10.040

2006-02-01

Abstract:

What problem does this paper attempt to address?

Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials

Xin-die Zhou,Li-jiang Tao,Jin Li,Li-dong Wu

DOI: https://doi.org/10.1007/s00402-013-1761-2

IF: 2.928

2013-01-01

Archives of Orthopaedic and Trauma Surgery

Abstract:Background Studies have shown that tranexamic acid reduces blood loss and transfusion need in patients undergoing total hip arthroplasty. However, no to date, no study has been large enough to determine definitively whether the drug is safe and effective. We examined whether intravenous tranexamic acid, when compared with placebo, was safe and effective in total hip arthroplasty. Methods The literature search was conducted using the PubMed, Cochrane Library, MEDLINE, EMBASE, and China National Knowledge Infrastructure (CNKI) databases. Data were evaluated using the generic evaluation tool designed by the Cochrane Bone, Joint and Muscle Trauma Group. Ultimately, 19 randomized controlled trials involving 1,030 patients were included. Results The use of tranexamic acid significantly reduced total blood loss by a mean of 305.27 mL [95 % confidence interval (CI) −397.66 to −212.89, p < 0.001], intraoperative blood loss by a mean of 86.33 mL(95 % CI −152.29 to −20.37, p = 0.01), postoperative blood loss by a mean of 176.79 mL (95 % CI −236.78 to −116.39, p < 0.001), and “hidden” blood loss by a mean of 152.70 mL (95 % CI −187.98 to −117.42, p < 0.001), resulting in a meaningful reduction in the proportion of patients requiring blood transfusion (odds ratio 0.28, 95 % CI 0.19 to 0.42, p < 0.001). There was no significant difference in occurrence of deep vein thrombosis, pulmonary embolism, or other complications among the study groups, or cost or hospitalization duration. Conclusions The data from this meta-analysis indicate that intravenous tranexamic acid may reduce blood loss and transfusion need in patients undergoing total hip arthroplasty without increasing the risk of complications. However, high-quality randomized controlled trials are required to validate the results.
Comparison of Intravenous Tranexamic Acid versus Combined Intravenous and Local Infiltration of Tranexamic Acid in Reducing Perioperative Blood Loss in Patients Undergoing Primary Unilateral Total Hip Arthroplasty: A Randomised Clinical Study

T Sita Rao,Monu Yadav,Akhya Kumar Kar,D Padmaja

DOI: https://doi.org/10.7860/jcdr/2023/60311.17837

2023-01-01

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH

Abstract:Introduction: The use of Tranexamic Acid (TXA) in primary unilateral Total Hip Arthroplasty (THA) is well documented. However, considering the potential side effects including deep vein thrombosis and pulmonary embolism, the ideal route of administration of TXA to patients undergoing THA is still not known. Aim: To compare the efficacy of single dose intravenous (i.v.) TXA administration versus combined intravenous and local infiltration of TXA in reducing the perioperative blood loss in primary unilateral THA patients. Materials and Methods: This prospective, randomised clinical study, was conducted in the Department of Anaesthesiology and Critical Care at Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India, between October 2020 to May 2021. 60 patients were randomly allocated into two groups: the combined group C (i.v. administration of 10 mg/kg of TXA combined with local infiltration of 600 mg TXA diluted to 60 mL with normal saline) and the single i.v. group S (i.v. administration of 10 mg/kg of TXA). The perioperative blood loss was calculated in terms of three variables- intraoperative blood loss, drainage blood loss and total blood loss. The number of postoperative blood transfusions noted. Student’s t-test and Fischer’s-exact tests were applied for statistical analysis. Results: A total of 60 patients scheduled to have primary unilateral THA. Both the groups were similar in demographic features, baseline biochemical values and procedural distribution. There was a statistically significant reduction in the (mean±SD) intraoperative blood loss (697.26±221.43 mL), drain blood volume (254.66±81.36 mL) and total blood loss (952.26±263.57 mL) in the combined group C when compared to the single group S. There was no statistically significant difference (p-value=0.671) in the postoperative blood transfusion rate between the two groups. Conclusion: Intravenous combined with local infiltration of TXA significantly reduced the perioperative blood loss in patients undergoing primary unilateral THA when compared to single dose intravenous administration of TXA.
Comparison of blood loss between intra-articular microporous polysaccharide hemospheres powder and tranexamic acid following primary total knee arthroplasty

Young-Dae Jeon,Jae-Ryong Cha,Jae-Min Oh,Sang-Gon Kim,Ki-Bong Park

DOI: https://doi.org/10.1038/s41598-024-55871-3

IF: 4.6

2024-03-03

Scientific Reports

Abstract:Total knee arthroplasty (TKA) is associated with substantial blood loss and tranexamic acid (TXA) effectively reduces postoperative bleeding. Although it is known that there is no difference between intravenous or intra-articular (IA) injection, the general interest is directed towards topical hemostatic agents regarding thromboembolic events in high-risk patients. This study aimed to compare the blood conservation effects of IA MPH powder and TXA in patients undergoing primary TKA. We retrospectively analyzed 103 patients who underwent primary TKA between June 2020 and December 2021. MPH powder was applied to the IA space before capsule closure (MPH group, n = 51). TXA (3 g) was injected via the drain after wound closure (TXA group, n = 52). All patients underwent drain clamping for three postoperative hours. The primary outcome was the drain output, and the secondary outcomes were the postoperative hemoglobin (Hb) levels during the hospitalization period and the perioperative blood transfusion rates. An independent Student's t-test was used to determine differences between the two groups. The drain output in the first 24 h after surgery was significantly higher in the MPH group than in the TXA group. The postoperative Hb levels were significantly lower in the MPH group than in the TXA group. In patients with simultaneous bilateral TKA, there was a significant difference in the blood transfusion volumes and the rates between groups. It is considered that IA MPH powder cannot replace IA TXA because of an inferior efficacy in reducing blood loss and maintaining postoperative Hb levels in the early postoperative period after primary TKA. Moreover, in the case of simultaneous bilateral TKA, we do not recommend the use of IA MPH powder because it was notably less effective in the field of transfusion volume and rate.

multidisciplinary sciences
Intravenous and subsequent long-term oral tranexamic acid in enhanced-recovery primary total knee arthroplasty without the application of a tourniquet: a randomized placebo-controlled trial

Hao-Yang Wang,Liu Wang,Ze-Yu Luo,Duan Wang,Xin Tang,Zong-Ke Zhou,Fu-Xing Pei

DOI: https://doi.org/10.1186/s12891-019-2885-5

IF: 2.562

2019-10-25

BMC Musculoskeletal Disorders

Abstract:Abstract Background To assess the efficacy and safety of intravenous and subsequent long-term oral tranexamic acid (TXA) following total knee arthroplasty (TKA) without a tourniquet. Methods In this double-blinded trial, 118 patients undergoing primary TKA were randomized into two groups: the patients in group A received intravenous TXA at 20-mg/kg 10 min before the surgery and 3 h postoperatively, and then oral 1 g TXA from postoperative day (POD) 1 to POD 14, and the patients in group B received intravenous TXA at 20-mg/kg 10 min before surgery and 3 h postoperatively, and then oral 1 g placebo from postoperative day (POD) 1 to POD 14. The primary outcome was total blood loss. Secondary outcomes included ecchymosis area and morbidity, postoperative transfusion, postoperative laboratory values, postoperative knee function and length of hospital stay. Complications, and patient satisfaction were also recorded. Results The mean total blood loss was lower in Group A than in Group B (671.7 ml vs 915.8 ml, P = 0.001). There was no significant difference in the transfusion rate between the two groups. Group A had a higher hemoglobin than Group B on POD 3 (106.0 g/L vs 99.7 g/L, P = 0.001). However, no significant difference was found for Hb or hematocrit on POD 1 or POD 14 between the two groups. Patients in Group A had less ecchymosis morbidity (7 vs 38, P = 0.001), smaller ecchymosis area (1.6 vs 3.0, P = 0.001) than Group B. The blood coagulation level as measured by fibrinolysis (D-Dimer) was lower in Group A than in Group B on POD 1 and POD 3 (4.6 mg/L vs. 8.4 mg/L, respectively, P = 0.001; 1.5 mg/L vs. 3.3 mg/L, respectively, P = 0.001). However, there was no significant difference on POD 14, and the fibrin degradation products showed the same trend. Patients in Group A had less swelling than those in Group B on POD 3 and POD 14. The circumference of the knee was 43.1 cm vs. 46.1 cm (POD 3, P = 0.001) and 41.4 cm vs. 44.9 cm (POD 14, P = 0.001) in Group A vs Group B, respectively. Nevertheless, the circumference of the knee in the two groups was similar on POD 1 and POD 3 M. No significant differences were identified in knee function, pain score, or hospital stay. No significant differences were identified in thromboembolic complications, infection, hematoma, wound healing and patients satisfaction between the two groups. Conclusion Intravenous and subsequent long-term oral TXA produced less blood loss and less swelling and ecchymosis compared with short-term TXA without increasing the risk of complications. Trial registration The trial was registered in the Chinese Clinical Trial Registry ( ChiCTR-IPR-17012264 ).

orthopedics,rheumatology
Effectiveness And Safety Of Tranexamic Acid In Reducing Blood Loss In Total Knee Arthroplasty: A Meta-Analysis

Zhi-Gao Yang,Wei-Ping Chen,Li-Dong Wu

DOI: https://doi.org/10.2106/JBJS.K.00873

2012-01-01

Abstract:Background: Total knee arthroplasty is associated with substantial blood loss and the risks of transfusion. Conflicting reports have been published regarding the effectiveness and safety of tranexamic acid in reducing postoperative blood loss in total knee arthroplasty. We performed a meta-analysis to investigate the effectiveness and safety of tranexamic acid in reducing postoperative blood loss in total knee arthroplasty.Methods: A meta-analysis was performed to assess the effectiveness and safety of using tranexamic acid in total knee arthroplasty. Randomized controlled trials that had been published before May 2011 were retrieved, and fifteen studies met the inclusion criteria. The weighted mean difference in blood loss, number of transfusions per patient, prothrombin time, and postoperative activated partial thromboplastin time and the summary odds ratio of transfusion, deep-vein thrombosis, and pulmonary embolism were calculated in the group of patients who received tranexamic acid and the group of patients who received a placebo.Results: The amount of blood loss and the number of blood transfusions per patient were significantly less and the proportion of patients who required a blood transfusion was smaller in the tranexamic acid group compared with the placebo group. No significant difference in prothrombin time, activated partial thromboplastin time, deep-vein thrombosis, and pulmonary embolism was detected between the tranexamic acid group and the placebo group.Conclusions: The meta-analysis shows that the use of tranexamic acid for patients undergoing total knee arthroplasty is effective and safe for the reduction of blood loss.
Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single‐Blind Randomized Controlled Trial

Xin-die Zhou,Yi Zhang,Li-feng Jiang,Jun-jie Zhang,Dong Zhou,Li-dong Wu,Yong Huang,Nan-wei Xu

DOI: https://doi.org/10.1111/os.12511

2019-01-01

Orthopaedic Surgery

Abstract:Objective To investigate the efficacy and safety of tranexamic acid (TXA) in the reduction of bleeding and the need for transfusion in elderly intertrochanteric fracture patients. Methods A total of 100 patients with intertrochanteric fractures undergoing surgery were enrolled and randomly allocated to the TXA group in which patients (75.10 ± 8.27 years old) were treated with 1 g of TXA, or the control group (77.82 ± 6.42 years old) treated with a placebo. Surgery was performed by two senior orthopaedic surgeons from two institutions. The proximal femoral nail antirotation (PFNA) was conducted using the standard procedure. Three outcome measures, including blood loss, transfusion, and complications, were recorded. Blood loss and transfusion were investigated to assess TXA's effectiveness, while complications were investigated to assess TXA's safety. Statistical indicators for blood loss included total, intraoperative, postoperative, and hidden blood loss volumes, calculated by hemoglobin levels, hematocrit levels, and drainage volume. The number and amount of blood transfusions were recorded. Complications associated with surgery, including deep vein thrombosis, pulmonary embolism, wound hematoma, wound infection, cardiovascular and cerebrovascular accidents, and respiratory infections, were also recorded. Results All patients were followed up for 1 month after surgery. There were no significant differences in demographic and clinical characteristics between the two groups. The TXA group suffered significantly less total blood loss (563.37 ± 197.51 vs 819.25 ± 273.96 mL, 95% CI : −349.49 to −162.27, P < 0.01), intraoperative blood loss (140.3 ± 80.64 vs 230.5 ± 130.56 mL, 95% CI −132.74 to −47.66, P < 0.01), and hidden blood loss (410.42 ± 178.23 vs 571.19 ± 218.13 mL, 95% CI : −238.85 to −82.69, P < 0.01) than the control group. However, postoperative total blood loss was not significantly different (97.5 ± 20.93 vs 94.7 ± 35.78 mL; P = 0.63). A total of 5 patients from the TXA group and 27 from the control group received packed RBC for postoperative transfusion, but the mean number of transfusion units was not significantly different between groups. Complications including deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic cerebral infarction, hematoma, and infection were observed in both groups, but no significant differences were found. Conclusions In intertrochanteric fracture surgery performed using PFNA, intravenous administration of TXA significantly reduced the risk of intraoperative, total and hidden blood loss, in addition to the need for allogeneic transfusion, without increasing the rate of complications.
Comparison of Hemocoagulase Atrox Versus Tranexamic Acid Used in Primary Total Knee Arthroplasty: A Randomized Controlled Trial.

Ji-Zheng Qin,Shao-Jie Wang,Xin-Peng Zheng,Hong-Hai Zhao,Yuan Lin,Lei Shi,Chun Xia

DOI: https://doi.org/10.1016/j.thromres.2020.02.001

IF: 10.407

2020-01-01

Thrombosis Research

Abstract:Background: Total knee arthroplasty (TKA) has been considered as an effective choice for end-stage osteoarthritis or rheumatic arthritis. Tranexamic acid (TXA) has been widely used to prevent excessive blood loss perioperatively. Similarly, hemocoagulase atrox can significantly diminish blood loss and transfusion requirements in surgeries, however, it was rarely used in TKA. The purpose of this study is to identify whether hemocoagulase atrox is equal to TXA in reducing blood loss and transfusion rates following TKA, and compare clinical outcomes and complications between the two groups. Methods: 74 patients were randomized to receive TXA (1.5 g intra-articular combined with 1.5 g intravenous), or hemocoagulase atrox (1 U intra-articular combined with 1 U intravenous). The primary outcome was total blood loss. The secondary outcomes included reduction of hemoglobin concentration, clinical outcomes, blood coagulation values, thromboembolic complications, and transfusion rates. Results: The mean total blood loss was 431.7 mL in the TXA group compared with 644.6 mL in the hemocoagulase atrox group, with statistical significance (P < 0.05). There were significant differences in reduction of hemoglobin level (P < 0.05). The rate of deep vein thrombosis (DVT) in patients given TXA was higher than those given hemocoagulase atrox, however, there were no significant differences. No transfusions were required in either group, and no significant differences were found in the length of hospital stay and clinical outcomes. Conclusions: Although the blood loss was significantly greater in the hemocoagulase atrox group, no transfusions were required and no significant differences were observed for any other outcomes measured. Meanwhile, the rate of DVT in the hemocoagulase atrox group tends to be lower than those in TXA group. We concluded that hemocoagulase atrox was not superior to TXA in reducing perioperative blood loss. Further studies are warranted to evaluate if hemocoagulase atrox use could improve perioperative blood loss in patients with high thrombotic risk undergoing TKA.
Impact of intraosseous regional administration of tranexamic acid in total knee arthroplasty on perioperative blood loss: a protocol for a randomised controlled trial

Zhanqi Wei,Muyang Yu,Yiming Xu,Xisheng Weng,Bin Feng,Wei,Z.,Yu,M.,Xu,Y.,Weng,X.,Feng,B.

DOI: https://doi.org/10.1136/bmjopen-2023-077393

IF: 3.006

2024-02-14

BMJ Open

Abstract:Introduction Total knee arthroplasty (TKA) is a common surgical intervention to treat joint diseases. However, TKA is associated with significant blood loss. Tranexamic acid (TXA) has been used to reduce perioperative bleeding and postoperative blood transfusion. This study aims to explore the effectiveness and safety of intraosseous regional administration (IORA) of TXA in TKA and compare differences in perioperative blood loss between IORA of TXA, intravenous infusion of TXA, and combined IORA and intravenous infusion of TXA. Methods and analysis This randomised controlled trial will enrol 105 patients with osteoarthritis who meet the inclusion criteria for unilateral TKA. Patients were randomly divided into three groups using the random number table method. Group A received 1.0 g of TXA via IORA, group B received 1.0 g of TXA via intravenous infusion 15 min prior to the tourniquet release, and group C received both IORA of 1.0 g of TXA and intravenous infusion of 1.0 g of TXA. The primary outcome measure is perioperative total blood loss. Secondary outcomes include bleeding events, venous thromboembolism events, inflammation reactions, other complications and knee function assessments. Ethics and dissemination This study has been approved by the Ethics Committee of Peking Union Medical College Hospital and registered in the Chinese Clinical Trial Registry. Informed consent will be obtained from all the patients before enrolment. The trial will be conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The results of this study will be disseminated through peer-reviewed publications, conference presentations and social media platforms. The findings will provide valuable insights into the use of IORA of TXA in TKA and may lead to the development of new strategies for perioperative blood management in joint replacement surgery. Trial registration number The Ethics Committee of Peking Union Medical College Hospital (approval number: K2371); Chinese Clinical Trial Registry (trial registration number: ChiCTR2200066293).

medicine, general & internal
The efficacy, safety, and cost-effectives of combined administration of Intravenous and Local Tranexamic Acid in the management of Patients Undergoing Primary Total Hip Arthroplasty: A prospective, blinded and randomized clinical study

Çağrı Örs,Remzi Çaylak

DOI: https://doi.org/10.5152/j.aott.2021.20397

Abstract:Objective: The aim of this study was to compare the efficacy, safety, and cost-effectiveness of combined administration of intravenous and local tranexamic acid with those of either intravenous or local administrations in patients undergoing primary total hip arthroplasty (THA). Methods: This prospective, blinded, and randomized clinical study was performed on patients undergoing unilateral primary THA from September 2018 to December 2019. A total of 90 patients were included and prospectively allocated to one of three groups: the combined group (n= 30, 14 male, 16 female; mean age = 54.9 ± 12 years), intravenous (IV) group (n = 30, 13 male, 17 female; mean age = 54.9 ± 12.3 years), and local group (n = 30, 13 male, 17 female; 50.3 ± 12.3). Tranexamic acid was used systemically by IV application (15mg/kg) in IV group, locally in the surgical field (2g) in local group as well as combined systemic and local together in combined group. The amount of blood loss, number of erythrocyte suspension transfusion, and changes in hemoglobin and hematocrit levels were documented accordingly. The estimated mean tranexamic acid and erythrocyte suspensions cost, extra nurse care, monitoring and laboratory costs associated with blood transfusion, and total hospital costs were compared among groups. Results: No differences existed in hemoglobin and hematocrit levels after surgery among the groups. The combined group required fewer blood transfusion compared to the local and IV groups, and the total amount of ES was statistically significantly lower (P = 0.039) in the combined group. Although the medication cost was higher in the combined group than in the other groups (P < 0.001), combined group was more cost-effective (P < 0.001) when the total costs related to blood loss were evaluated. No occurrence of deep vein thrombosis or pulmonary embolism was found in the study. Conclusion: Combined administration of IV and local tranexamic acid seems to be more effective in reducing the requirement and amount of blood transfusion without increasing the risk of thromboembolic complications in primary THA compared to IV or local administrations. Despite increasing the prophylaxis costs, combined administration of TXA can result in lower total hospitalization costs by decreasing blood loss and consequent treatment costs in primary THA. Level of evidence: Level I, Randomized Controlled Trial.
Total-energy calculations for intermetallic compounds with a first-principles linear combination of atomic orbitals method.

Hafner,Weber

DOI: https://doi.org/10.1103/PHYSREVB.33.747

1986-01-15

Abstract:
Combined use of intravenous and topical tranexamic acid in patients aged over 70 years old undergoing total hip arthroplasty

Junqing Jia

DOI: https://doi.org/10.1186/s13018-019-1384-6

2019-11-07

Abstract:Purpose: The present study was designed to evaluate the efficacy and safety of combined use of intravenous (IV) TXA administration and topical intraarticular tranexamic acid (TXA) strategy in patients aged over 70 undergoing total hip arthroplasty (THA). Methods: One hundred eighty patients were randomized into three groups, including an IV group, a local group, and a combined group. Patients were administrated with 15 mg/kg of IV-TXA in the IV group, 2 g TXA in the topical group, or 15 mg/kg IV-TXA combined with 2 g TXA in the combined group. Total blood loss (TBL), maximum hemoglobin drop, the transfusion rate and the number of allogeneic blood units, and the incidence of deep venous thrombosis (DVT), and pulmonary embolism (PE) were recorded and analyzed. Results: TBL was 757.75 ± 188.95 mL in the combined group, which was significantly lower than in the IV group (892.75 ± 218.47) or the topical group (1015.75 ± 288.71) (p = 0.015, p = 0.001 respectively). The mean values of maximum hemoglobin drop in the combined, IV, and topical groups were 2.67 ± 0.42, 3.28 ± 0.52, and 3.75 ± 0.62 g/dL, respectively, with a significant intergroup difference (p < 0.001 for all). PE was not detected within 1 month after the surgery. Asymptomatic DVT was reported in 1 patient of the IV group, and in 2 patients from the combined group, while the difference was not statistically significant. Conclusions: Compared to intravenous or topical use of TXA, the combined therapy effectively decreased total blood loss and reduced the transfusion rate, simultaneously possessed the same degree of safety in primary THA patients aged over 70.
The spatial dependency of shoulder muscular demands during upward and downward exertions

Alicia L. Nadon,Meghan E. Vidt,A. Chow,C. Dickerson

DOI: https://doi.org/10.1080/00140139.2015.1136697

IF: 2.5612

2016-02-25

Ergonomics

Abstract:Abstract Lifting and lowering are common occupational tasks contributing to shoulder injury risk. Quantifying task interaction with physical demand can precipitate better workstation designs. Nineteen university-aged males performed one-handed, submaximal upward/downward manual force exertions at 70 hand locations; unilateral electromyography (EMG) of 14 muscles was recorded. EMG across planes was evaluated with ANOVA. Predictive equations for muscle activity throughout the reach envelope were developed with stepwise regression. Total muscle activity (sum of individual muscle activity) was most sensitive to vertical hand location for upward exertions, where activation at superior locations was 192% of values for inferior locations. For upward exertions, activation differences for hand location occurred along all anatomical axes, and along anterior/posterior and superior/inferior axes for downward exertions. Predictive equations were non-linear, reflecting complex muscular demand with three-dimensional hand location. This work details foundational exposure data for lifting/lowering exertions. Results are applicable to workstation design to minimise occupational shoulder muscular demands. Practitioner Summary: Lifting and lowering in the workplace contribute to shoulder injury risk. Shoulder muscle activity magnitudes revealed a dependence on three-dimensional hand location in the reach envelope for a defined hand force. This information can inform evidence-based workstation designs that reduce shoulder muscular demands for numerous materials handling scenarios.
Patient expectation is the most important predictor of discharge destination after primary total joint arthroplasty.

M. J. Halawi,Tyler J. Vovos,C. Green,S. Wellman,D. Attarian,M. Bolognesi

DOI: https://doi.org/10.1016/j.arth.2014.10.031

2015-04-01

Abstract:
Application of Tranexamic Acid in Total Knee Arthroplasty – Prospective Randomized Trial

Joao Paulo Fernandes Guerreiro,Bruno Scatolon Badaro,Jose Rodolfo Martines Balbino,Marcus Vinicius Danieli,Alexandre Oliveira Queiroz,Daniele Cristina Cataneo

DOI: https://doi.org/10.2174/1874325001711011049

2017-08-29

The Open Orthopaedics Journal

Abstract:Background: The use of tranexamic acid (TXA) in total knee arthroplasty (TKA) has shown good results. Bleeding may cause local complications consequently greater pain and reduced function postoperatively. No study has related the use of TXA to these facts. Objective: The aim was to evaluate the effects of TXA haemoglobin, Western Ontario and McMaster Universities Index (WOMAC), pain intensity and flexion gain after TKA. Methods: 43 patients were randomized and then underwent TKA. TXA was applied to 22 of these patients before closure of the joint capsule. Haemoglobin measurements (mg/dL) were taken preoperatively and 24 and 48 hours after surgery. The WOMAC questionnaire and pain visual analogue scale (VAS) were applied, and flexion gain was measured up to the second postoperative month. Statistical analysis compared the results to determine whether there were differences between the groups for each of the evaluated times. Results: There were differences in favour of the drug 48 hours postoperatively for the haemoglobin variable (p = 0.01), in pain evaluation, 24 and 48 hours, postoperatively (p < 0.01) and in flexion gain, 24 hours after surgery (p = 0.03). There were no significant differences between the groups in the haemoglobin evaluation 24 hours postoperatively, in pain assessment 7 days, 21 days and 2 months, postoperatively, in flexion gain 48 hours, 7 days, 21 days and 2 months, postoperatively and in WOMAC after 2 months. Conclusion: In addition to reducing bleeding, topical TXA improved pain and increased flexion gain in the first hours after TKA. Trial Registration: RBR-9b4qgq
Intra-articular Vs. Intravenous Administration: a Meta-Analysis of Tranexamic Acid in Primary Total Knee Arthroplasty

Jin Li,Ruikang Liu,Saroj Rai,Renhao Ze,Xin Tang,Pan Hong

DOI: https://doi.org/10.1186/s13018-020-02119-1

IF: 2.6

2020-01-01

Journal of Orthopaedic Surgery and Research

Abstract:Background The optimal dosage and administration approach of tranexamic acid (TXA) in primary total knee arthroplasty (TKA) remains controversial. In light of recently published 14 randomized controlled trials (RCTs), the study aims to incorporate the newly found evidence and compare the efficacy and safety of intra-articular (IA) vs. intravenous (IV) application of TXA in primary TKA. Methods PubMed, Embase, Web of Science, and Cochrane Library were searched for RCTs comparing IA with IV TXA for primary TKA. Primary outcomes included total blood loss (TBL) and drain output. Secondary outcomes included hidden blood loss (HBL), hemoglobin (Hb) fall, blood transfusion rate, perioperative complications, length of hospital stay, and tourniquet time. Result In all, 34 RCTs involving 3867 patients were included in our meta-analysis. Significant advantages of IA were shown on TBL (MD = 33.38, 95% CI = 19.24 to 47.51, P < 0.001), drain output (MD = 28.44, 95% CI = 2.61 to 54.27, P = 0.03), and postoperative day (POD) 3+ Hb fall (MD = 0.24, 95% CI = 0.09 to 0.39, P = 0.001) compared with IV. There existed no significant difference on HBL, POD1 and POD2 Hb fall, blood transfusion rate, perioperative complications, length of hospital stay, and tourniquet time between IA and IV. Conclusion Intra-articular administration of TXA is superior to intravenous in primary TKA patients regarding the performance on TBL, drain output, and POD3+ Hb fall, without increased risk of perioperative complications. Therefore, intra-articular administration is the recommended approach in clinical practice for primary TKA.
Comparative effectiveness of combined peri-articular and intra-articular injection versus intravenous and intra-articular injection of tranexamic acid in total knee arthroplasty: a randomized controlled trial study

Piya Pinsornsak,Ranet Thaveekitikul,Prem Pinsornsak,Yot Tanariyakul

DOI: https://doi.org/10.1007/s00402-024-05337-y

IF: 2.928

2024-04-27

Archives of Orthopaedic and Trauma Surgery

Abstract:Tranexamic acid (TXA) administration is supported by numerous evidence in reducing blood loss after total knee arthroplasty (TKA). The combination of intravenous (IV) and intra-articular (IA) TXA administration revealed good result in blood loss reduction with less evidence of venous thromboembolism event (VTE). Several literature reviews portray that peri-articular (PA) administration yields similar hemostasis in comparison to IV route. However, there is no report on the clinical effect of combining PA + IA TXA in blood loss reduction and its complications, compared to combining IV + IA TXA after TKA.

surgery,orthopedics
Comparison of oral versus intravenous tranexamic acid in total knee and hip arthroplasty: A GRADE analysis and meta-analysis

Changjiao Sun,Xiaofei Zhang,Lianxu Chen,Jiuzheng Deng,Qi Ma,Xu Cai,Huadong Yang

DOI: https://doi.org/10.1097/MD.0000000000022999

2020-10-30

Abstract:Background: The efficacy and safety of oral tranexamic acid (TXA) remain controversial because of the small number of clinical studies. The aim of the present study was to compare the efficacy and safety of oral TXA with intravenous TXA in patients undergoing total hip arthroplasty and total knee arthroplasty in a systematic review and meta-analysis. Methods: We conducted a meta-analysis to identify randomized controlled trials (RCTs) involving oral and intravenous TXA in total hip arthroplasty and total knee arthroplasty up to December 2019 by searching databases including PubMed, Web of Science, Embase, the Cochrane Controlled Trials Register, the Cochrane Library China Biology Medicine, China National Knowledge Infrastructure, China Science and Technology Journal Database and Wanfang. The mean difference or standard mean difference was used to assess continuous outcomes such as hemoglobin (Hb) drop, total blood loss, drain blood loss, and length of hospital stay, with a 95% confidence interval. Relative risks with a 95% confidence interval were used to assess dichotomous outcomes such as transfusion rate and the incidence of deep venous thrombosis and calf muscular vein thrombosis. Review Manager was used for the meta-analysis. Results: Ten RCTs containing 1080 participants met the inclusion criteria. We found no significant differences in terms of the average Hb drop (P = .60), total blood loss (P = .60), transfusion rate (P = .99), drain blood loss (P = .91), length of hospital stay (P = .95), and the incidence of deep venous thrombosis (P = .55) and calf muscular vein thrombosis (P = .19) between oral and IV TXA. Conclusions: Compared with the IV TXA, oral TXA has similar effects on reducing the Hb drop, total blood loss, transfusion rate, drain blood loss, and length of hospital stay without increasing the risk of calf muscular vein thrombosis and deep venous thrombosis. Furthermore, oral TXA is easy to access and administer, which decreases the workload of nurses and even delivers cost-saving benefits to the health care system. We thus conclude that oral TXA may be an optimal approach in total joint arthroplasty. However, more high-quality and multicenter RCTs are still needed to confirm our conclusions. Registration: The current meta-analysis was registered on PROSPERO (International Prospective Register of Systematic Reviews), and the registration number was CRD42018111291.
MEG and EEG in epilepsy: is there a difference?

C. Guy,S. Walker,G. Alarcón,C. Binnie,P. Chesterman,P. Fenwick,S. Smith

DOI: https://doi.org/10.1088/0967-3334/14/4A/018

1993-11-01

Physiological Measurement

Abstract:Interictal epileptiform activity recorded by scalp EEG, foramen ovale electrodes and MEG is discussed. Gross differences in waveform between the electric and magnetic records are discussed in the light of intracranial depth recordings.
Clinical Efficacy of Intra‐articular Tranexamic Acid Injection in the Management of Hemophilia with Total Hip Arthroplasty: A 24‐month Retrospective Cohort Study

Hai Su,Hua Huang,Sicheng Xiang,Yichen Gong,Haojing Zhou,Lei Chen,Zhongyi Zhang,Peijian Tong,Taotao Xu

DOI: https://doi.org/10.1111/os.14126

2024-06-05

Orthopaedic Surgery

Abstract:This study confirms that intra‐articular injection of tranexamic acid (TXA) during joint surgery can effectively reduce blood loss in patients undergoing total hip arthroplasty (THA) with hemophilia. It is noteworthy that this method not only proves effective in alleviating early postoperative pain but also enables hemophilic patients to achieve higher hip joint scores and improved joint mobility. Interestingly, in addition to reducing intraoperative blood loss, this method appears not to increase the risk of thromboembolism in patients. Moreover, it has a positive effect on slowing down the postoperative inflammatory response. Simultaneously, the use of TXA may reduce postoperative nutritional loss, leading to improved wound healing and recovery for patients. Intra‐articular injection of TXA may serve as an effective and safe hemostatic method in joint surgery. Future research should involve the design of more precise prospective studies to assess the long‐term effects of TXA in these patients and evaluate its safety in different patient populations. Objective Total hip arthroplasty (THA) effectively treats end‐stage hemophilic hip arthropathy. Given hemophilia's unique characteristics, perioperative bleeding remains a significant risk for patients undergoing THA. Tranexamic acid (TXA), an efficient antifibrinolytic agent, may benefit the outcomes of THA for patients with hemophilia (PWH). This study aims to explore the clinical efficacy of intra‐articular injection of TXA in treating perioperative bleeding in PWH and assess its additional clinical benefits. Methods The retrospective study comprised data of PWH who received THA from January 2015 to December 2021 in the research center. A total of 59 individuals were included in the study, divided into a TXA group (n = 31) and a non‐TXA group (n = 28). We compared various parameters, including total blood loss (TBL), visible blood loss (VBL), occult blood loss (OBL), intraoperative coagulation factor VIII (FVIII) consumption, perioperative total FVIII consumption, hemoglobin (HB), erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP), length of hospital stay, hospitalization costs, length of surgery, total protein, activated partial thromboplastin time (APTT), D‐dimer, rate of joint swelling, hip joint range of motion (ROM), visual analogue scale (VAS), and Harris hip joint function scale (HHS) between the two groups. Follow‐up assessments were conducted for up to 24 months. A Student's t test was utilized for the statistical analysis. Results This study demonstrated that intra‐articular TXA effectively reduced TBL (1248.19 ± 439.88 mL, p

orthopedics
Repeated doses of intravenous tranexamic acid are effective and safe at reducing perioperative blood loss in total knee arthroplasty.

Qintong Xu,Yi Yang,Peng Shi,Jian Zhou,Wenda Dai,Zhenjun Yao,Chi Zhang

DOI: https://doi.org/10.5582/bst.2014.01063

2014-01-01

BioScience Trends

Abstract:Fibrin sealant (FS) and tranexamic acid (TXA) have been used in total knee arthroplasty (TKA) to minimize perioperative blood loss. The efficacy of FS has been debated, and few studies have looked into the effects of FS and TXA on perioperative coagulability. The current study retrospectively reviewed 100 cases of unilateral primary TKA. Twenty-five cases served as blank controls, FS was used without TXA in 23, TXA was used without FS in 20, and both FS and TXA (FS + TXA) were used in 32. FS was sprayed before wound closure whereas 1 g of TXA was intravenously administered before incision and 1 g was administered 15 min before tourniquet release. Hematocrit and hemoglobin levels and thromboelastography (TEG) parameters were assessed pre-operatively and on day 1, 4, and 9 post-operatively. Blood transfusions were noted and the incidence of symptomatic DVT/PE was determined. Hematocrit and hemoglobin levels were significantly higher in the TXA and FS + TXA groups compared to the control and FS groups on day 1, 4, and 9 post-operatively. Hematocrit and hemoglobin levels in the control group were similar to those in the FS group and hematocrit and hemoglobin levels in the TXA group were similar to those in the FS + TXA group. TEG parameters (R, K, alpha, MA, and CI) remained within normal ranges. Mean CI was less than + 3 in all four groups, suggesting that hypercoagulation was not promoted. One patient in the FS group received an allogeneic transfusion. Incidence of symptomatic DVT/PE was not noted. Intravenous TXA significantly reduced perioperative blood loss in patients undergoing a TKA but FS did not. Administration of FS in addition to TXA was not superior to TXA alone. FS and/or TXA did not increase the risk of hypercoagulation according to TEG parameters. Intravenous administration of 1 g of TXA pre-operatively and administration of 1 g before tourniquet release is an effective and safe method of reducing blood loss in TKA.

Management of empyema cavity with the vacuum-assisted closure device.

Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials

Comparison of Intravenous Tranexamic Acid versus Combined Intravenous and Local Infiltration of Tranexamic Acid in Reducing Perioperative Blood Loss in Patients Undergoing Primary Unilateral Total Hip Arthroplasty: A Randomised Clinical Study

Comparison of blood loss between intra-articular microporous polysaccharide hemospheres powder and tranexamic acid following primary total knee arthroplasty

Intravenous and subsequent long-term oral tranexamic acid in enhanced-recovery primary total knee arthroplasty without the application of a tourniquet: a randomized placebo-controlled trial

Effectiveness And Safety Of Tranexamic Acid In Reducing Blood Loss In Total Knee Arthroplasty: A Meta-Analysis

Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single‐Blind Randomized Controlled Trial

Comparison of Hemocoagulase Atrox Versus Tranexamic Acid Used in Primary Total Knee Arthroplasty: A Randomized Controlled Trial.

Impact of intraosseous regional administration of tranexamic acid in total knee arthroplasty on perioperative blood loss: a protocol for a randomised controlled trial

The efficacy, safety, and cost-effectives of combined administration of Intravenous and Local Tranexamic Acid in the management of Patients Undergoing Primary Total Hip Arthroplasty: A prospective, blinded and randomized clinical study

Total-energy calculations for intermetallic compounds with a first-principles linear combination of atomic orbitals method.

Combined use of intravenous and topical tranexamic acid in patients aged over 70 years old undergoing total hip arthroplasty

The spatial dependency of shoulder muscular demands during upward and downward exertions

Patient expectation is the most important predictor of discharge destination after primary total joint arthroplasty.

Application of Tranexamic Acid in Total Knee Arthroplasty – Prospective Randomized Trial

Intra-articular Vs. Intravenous Administration: a Meta-Analysis of Tranexamic Acid in Primary Total Knee Arthroplasty

Comparative effectiveness of combined peri-articular and intra-articular injection versus intravenous and intra-articular injection of tranexamic acid in total knee arthroplasty: a randomized controlled trial study

Comparison of oral versus intravenous tranexamic acid in total knee and hip arthroplasty: A GRADE analysis and meta-analysis

MEG and EEG in epilepsy: is there a difference?

Clinical Efficacy of Intra‐articular Tranexamic Acid Injection in the Management of Hemophilia with Total Hip Arthroplasty: A 24‐month Retrospective Cohort Study

Repeated doses of intravenous tranexamic acid are effective and safe at reducing perioperative blood loss in total knee arthroplasty.